Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day. By comparison, the S&P 500 (^GSPC -0.77%) dipped by only 0.8% that trading session.The top line found wantingBeam, which is still in the clinical stage, earned slightly under $7.5 million in its first quarter of the year on license and collaboration revenue. That w ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.71%. A quarter ago, it was expected that this company would post a loss of $1.10 per share when it actually produced a loss of $1.09, delivering a surprise of 0.91%.Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other jurisdic ...

Exhibit 99.1 Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fou ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Pre ...

Core Insights - Beam Therapeutics presented new data from the Phase 1/2 clinical trial of BEAM-302, showing a mean of 91% corrected M-AAT in circulation at Day 28 in the 60 mg cohort, alongside a 79% decrease in mutant Z-AAT levels [1][3][4] Group 1: Clinical Trial Data - The Phase 1/2 trial of BEAM-302 has demonstrated positive initial safety and efficacy, establishing clinical proof of concept for treating alpha-1 antitrypsin deficiency (AATD) [2] - Updated biomarker data from the 60 mg cohort indicated that the proportion of corrected M-AAT reached a mean of 91% of total AAT in circulation, surpassing levels typically seen in patients with the MZ genotype [3] - The treatment led to a mean decrease of 79% in circulating mutant Z-AAT from baseline as of Day 28 [3] Group 2: Future Plans and Developments - Beam Therapeutics plans to continue the dose-escalation portion of the trial, initiating a fourth cohort at 75 mg and expects to present further data at a medical conference in the second half of 2025 [4] - The company aims to dose the first patient in Part B of the trial, which will include AATD patients with mild to moderate liver disease, in the second half of 2025 [4] - The investigational drug application (IND) for BEAM-302 has been cleared by the U.S. FDA, allowing the activation of trial sites in the U.S. [4] Group 3: About BEAM-302 and AATD - BEAM-302 is a liver-targeting lipid-nanoparticle formulation designed to correct the PiZ mutation, which is prevalent among patients with severe AATD [5] - The treatment aims to reduce the aggregation of mutant AAT protein, generate therapeutic levels of corrected protein, and increase total AAT in circulation, addressing the underlying pathophysiology of liver and lung disease [5] - AATD is an inherited genetic disorder that can lead to early onset emphysema and liver disease, with an estimated 100,000 individuals in the U.S. affected by the severe form of the disease [6][8]

Beam Therapeutics Inc. (BEAM) announced that the FDA has cleared the investigational new drug (IND) application to begin clinical studies on its pipeline candidate, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD) in the United States.BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the disease-causing PiZ mutation.AATD is an inherited genetic disorder that can cause early onset of emphysema and liver disease. Currently, ther ...

Core Viewpoint - The FDA has cleared the investigational new drug (IND) application for BEAM-302, a potential treatment for alpha-1 antitrypsin deficiency (AATD), marking a significant advancement in the development of genetic medicines for this condition [2][3]. Company Overview - Beam Therapeutics is a biotechnology company focused on precision genetic medicines through base editing, with a commitment to developing a fully integrated platform for gene editing, delivery, and manufacturing [8]. Product Details - BEAM-302 is a liver-targeting lipid-nanoparticle formulation designed to correct the PiZ mutation in patients with AATD, which is expected to provide a one-time treatment option [3][5]. - The ongoing Phase 1/2 clinical trial of BEAM-302 aims to evaluate its safety, tolerability, pharmacodynamics, pharmacokinetics, and efficacy, with initial results indicating proof of concept for the treatment [3][4]. Clinical Trial Progress - The company plans to continue the dose-escalation portion of the trial and expects to report further data at a medical conference in the second half of 2025, including the initiation of dosing for patients with mild to moderate liver disease [4][3]. Disease Background - AATD is an inherited genetic disorder that can lead to early onset emphysema and liver disease, primarily affecting individuals with the PiZZ genotype, which is estimated to be present in about 100,000 individuals in the U.S. [6][7]. - Current treatments for AATD are limited, with no curative options available, highlighting the potential impact of BEAM-302 [7].

Beam Therapeutics Inc. (BEAM) announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 antitrypsin deficiency (AATD).Currently, there are no approved curative treatments for the given indication.Data from the study showed that treatment with a single dose of BEAM-302 demonstrated durable, dose-dependent increases in total and functional alpha-1 antitrypsin (AAT). Also, new production of corrected pro ...

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant, before deducting underwri ...